1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Moxifloxacin Liquid Formulation

Manufacturer or supplier's details
Company : MSD
Address : 199 Wenhai North Road
       : HEDA, Hangzhou - Zhejiang Province - CHINA 310018
Telephone : 908-740-4000
Emergency telephone number : 86-571-87268110
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical

2. HAZARDS IDENTIFICATION

Emergency Overview
Appearance : liquid
Colour : yellow
Odour : odourless

Not a hazardous substance or mixture.

GHS Classification
Not a hazardous substance or mixture.

GHS label elements
Not a hazardous substance or mixture.

Physical and chemical hazards
Not classified based on available information.

Health hazards
Not classified based on available information.

Environmental hazards
Not classified based on available information.

Other hazards which do not result in classification
None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components
Moxifloxacin Liquid Formulation

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air. Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : None known.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during firefighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : No hazardous combustion products are known

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSOAL PROTECTION section.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Avoid inhalation of vapour or mist. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact: Oxidizing agents

Storage

Conditions for safe storage: Keep in properly labelled containers. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents

Packaging material: Unsuitable material: None known.
Moxifloxacin Liquid Formulation

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moxifloxacin HCL</td>
<td>186826-86-8</td>
<td>TWA</td>
<td>1000 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures:
Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection:
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type:
Particulates type

Eye/face protection:
Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection:
Work uniform or laboratory coat.

Hand protection:
Material:
Chemical-resistant gloves

Hygiene measures:
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: liquid

Colour: yellow

Odour: odourless

Odour Threshold: No data available
Moxifloxacin Liquid Formulation

10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Moxifloxacin Liquid Formulation

Stability:
- Stable under normal conditions.
- Can react with strong oxidizing agents.

Conditions to avoid:
- None known.

Incompatible materials:
- Oxidizing agents

Hazardous decomposition products:
- No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity:
Not classified based on available information.

Components:

Moxifloxacin HCL:
Acute oral toxicity:
- LD50 (Rat): 1,320 mg/kg
- LD50 (Mouse): > 435 mg/kg
- LD50 (Monkey): 1,500 mg/kg

Skin corrosion/irritation:
Not classified based on available information.

Components:

Moxifloxacin HCL:
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation:
Not classified based on available information.

Components:

Moxifloxacin HCL:
Species: Rabbit
Result: Moderate eye irritation

Respiratory or skin sensitisation:

Skin sensitisation:
Not classified based on available information.

Respiratory sensitisation:
Not classified based on available information.
Germ cell mutagenicity
Not classified based on available information.

Components:

Moxifloxacin HCL:
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: positive
- Test Type: Chromosome aberration test in vitro
  Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  Result: negative
- Test Type: in vitro micronucleus test
  Result: negative

Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  Application Route: Oral
  Result: negative

Carcinogenicity
Not classified based on available information.

Reproductive toxicity
Not classified based on available information.

Components:

Moxifloxacin HCL:
Effects on fertility:
- Test Type: Fertility/early embryonic development
  Species: Rat
  Application Route: Oral
  Fertility: LOAEL: 500 mg/kg body weight
  Result: Effects on fertility

Effects on foetal development:
- Test Type: Embryo-foetal development
  Species: Monkey
  Application Route: Oral
  Developmental Toxicity: NOAEL: 10 mg/kg body weight
  Result: negative
- Test Type: Embryo-foetal development
  Species: Rabbit
  Application Route: Intravenous injection
  Developmental Toxicity: LOAEL: 20 mg/kg body weight
  Symptoms: Skeletal malformations

Reproductive toxicity - Assessment:
Some evidence of adverse effects on development, based on animal experiments.
STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Components:

Moxifloxacin HCL:
Target Organs: Liver
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Moxifloxacin HCL:
Species: Rat
LOAEL: 100 mg/kg
Application Route: Oral
Exposure time: 4 Weeks

Species: Rat
NOAEL: 100 mg/kg
Application Route: Oral
Exposure time: 13 Weeks
Target Organs: Liver
Symptoms: Liver disorders

Species: Rat
NOAEL: 20 mg/kg
Application Route: Oral
Exposure time: 6 Months
Target Organs: Liver
Symptoms: Liver disorders

Species: Monkey
NOAEL: 50 mg/kg
Application Route: Oral
Exposure time: 4 Weeks
Symptoms: No adverse effects

Species: Monkey
NOAEL: 15 mg/kg
Application Route: Oral
Exposure time: 13 Weeks
Target Organs: Gastrointestinal tract
Symptoms: Vomiting

Species: Monkey
Application Route: Oral
Exposure time: 26 Weeks
Target Organs: Liver
Moxifloxacin Liquid Formulation

Symptoms : Liver disorders

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Moxifloxacin HCL:
Ingestion : Symptoms: Nausea, Abdominal pain, Headache, Dizziness, central nervous system effects, joint pain

12. ECOLOGICAL INFORMATION

Ecotoxicity
No data available

Persistence and degradability
No data available

Bioaccumulative potential
No data available

Mobility in soil
No data available

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Moxifloxacin Liquid Formulation

Version 1.5  Revision Date: 09/13/2019  SDS Number: 1731695-00006  Date of last issue: 2019/04/24
Date of first issue: 2017/06/05

GB 6944/12268
Not regulated as a dangerous good

Special precautions for user
Not applicable

15. REGULATORY INFORMATION

National regulatory information
Law on the Prevention and Control of Occupational Diseases

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

16. OTHER INFORMATION

Further information
Date format : yyyy/mm/dd

Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Develop-
Moxifloxacin Liquid Formulation

Version   Revision Date:   SDS Number:   Date of last issue: 2019/04/24
1.5       09/13/2019     1731695-00006   Date of first issue: 2017/06/05

Disclaimer
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

CN / EN